<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Arginase Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Arginase Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>Arginase Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0008814" target="_blank">
                        MONDO:0008814
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Urea Cycle Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Arginase 1 (ARG1) deficiency is a rare autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in the ARG1 gene. ARG1 catalyzes the final step of the urea cycle, hydrolyzing L-arginine to ornithine and urea. Loss of ARG1 activity leads to persistent hyperargininemia and accumulation of neurotoxic guanidino compounds, with relatively infrequent hyperammonemia compared to other urea cycle disorders. The hallmark clinical presentation includes progressive spastic diplegia or paraparesis, seizures, intellectual disability, and growth retardation, typically manifesting in early childhood. The estimated global birth prevalence is approximately 2.8 per 1,000,000 live births.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">12</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">ARG1 molecular function deficiency</div>
                
                <div class="item-desc">Biallelic pathogenic ARG1 variants reduce arginase catalytic activity in hepatocytes.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        ARG1
                        
                    </span>
                    
                </div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        liver
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."</div>
                
                
                <div class="evidence-explanation">Supports ARG1 deficiency as the initiating molecular defect in arginase deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired ureagenesis and hyperargininemia</div>
                
                <div class="item-desc">Loss of ARG1 activity causes persistent hyperargininemia with plasma arginine levels exceeding 300 umol/L, impaired nitrogen disposal, and intermittent hyperammonemia during catabolic stress. Unlike other urea cycle disorders, hyperammonemia is relatively infrequent, and the dominant disease driver is chronic arginine toxicity.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        urea cycle
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000050" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        arginine catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006527" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38292042" target="_blank">PMID:38292042</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality."</div>
                
                
                <div class="evidence-explanation">Confirms hyperargininemia as the central biochemical feature of ARG1-D.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neurotoxicity from guanidino compound accumulation</div>
                
                <div class="item-desc">Accumulation of arginine and its downstream guanidino compound derivatives contributes to neurotoxicity through multiple mechanisms including inhibition of GABAergic and glycinergic neurotransmission, disruption of Na+/K+-ATPase activity, and induction of oxidative stress in brain tissue. These neurotoxic effects underlie the progressive neurological deterioration characteristic of the disease.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        synaptic transmission, GABAergic
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051932" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        brain
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This review briefly highlights the current understanding of the etiology and pathophysiology of ARG1 deficiency derived from clinical case reports and therapeutic strategies stretching over several decades and reports on several exciting new developments regarding the pathophysiology of the..."</div>
                
                
                <div class="evidence-explanation">Reviews pathophysiology of ARG1 deficiency but the abstract does not specifically detail guanidino compound neurotoxic mechanisms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">White matter pathology and dysmyelination</div>
                
                <div class="item-desc">Central nervous system white matter pathology with dysmyelination and corticospinal tract degeneration is a key substrate for progressive spasticity in ARG1 deficiency. Preclinical studies demonstrate that hepatic ARG1 restoration via mRNA therapy can improve CNS myelination in arginase-deficient mice, suggesting that systemic arginine reduction has downstream CNS benefits.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        oligodendrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000128" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        myelination
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042552" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        white matter
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002316" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39449289" target="_blank">PMID:39449289</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency, in the latter case has progressed to the clinical trials phase."</div>
                
                
                <div class="evidence-explanation">Confirms preclinical mRNA therapy testing for arginase deficiency but does not specifically address myelination outcomes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical presentation and progression were evident in our series."</div>
                
                
                <div class="evidence-explanation">Clinical evidence of progressive spasticity consistent with corticospinal tract and white matter pathology.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Arginine-nitric oxide pathway dysregulation</div>
                
                <div class="item-desc">Arginine is a shared substrate for arginase and nitric oxide synthase (NOS). Loss of ARG1 activity shifts arginine partitioning and may perturb nitric oxide and polyamine biosynthesis, with implications for vascular function and cellular signaling. ARG1 is also expressed in erythrocytes and immune cells, suggesting broader metabolic consequences beyond the hepatic urea cycle.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        erythrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        nitric oxide biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006809" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Finally, some of the functions and implications of ARG1 in non-urea cycle activities are considered."</div>
                
                
                <div class="evidence-explanation">Mentions non-urea cycle ARG1 activities but does not specifically detail NO pathway dysregulation in the abstract.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Neurotoxicity_from_guanidino_compound_accumulation[&#34;Neurotoxicity from guanidino compound accumulation&#34;]
    White_matter_pathology_and_dysmyelination[&#34;White matter pathology and dysmyelination&#34;]
    ARG1_molecular_function_deficiency[&#34;ARG1 molecular function deficiency&#34;]
    Arginine_nitric_oxide_pathway_dysregulation[&#34;Arginine-nitric oxide pathway dysregulation&#34;]
    Impaired_ureagenesis_and_hyperargininemia[&#34;Impaired ureagenesis and hyperargininemia&#34;]

    ARG1_molecular_function_deficiency --&gt; Impaired_ureagenesis_and_hyperargininemia
    Impaired_ureagenesis_and_hyperargininemia --&gt; Neurotoxicity_from_guanidino_compound_accumulation
    Impaired_ureagenesis_and_hyperargininemia --&gt; Arginine_nitric_oxide_pathway_dysregulation
    Neurotoxicity_from_guanidino_compound_accumulation --&gt; White_matter_pathology_and_dysmyelination

    style Neurotoxicity_from_guanidino_compound_accumulation fill:#dbeafe
    style White_matter_pathology_and_dysmyelination fill:#dbeafe
    style ARG1_molecular_function_deficiency fill:#dbeafe
    style Arginine_nitric_oxide_pathway_dysregulation fill:#dbeafe
    style Impaired_ureagenesis_and_hyperargininemia fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">12</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Head and Neck<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Nervous System<span class="pill-count">(5)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Growth<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Other<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatomegaly
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002240" target="_blank">
                                Hepatomegaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002240)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hepatomegaly has been reported in case reports of ARG1 deficiency but robust frequency data are lacking.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Microcephaly
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000252" target="_blank">
                                Microcephaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000252)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Microcephaly has been reported in some ARG1-deficient patients but the abstract does not specifically quantify this finding.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Spasticity
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001257" target="_blank">
                                Spasticity
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001257)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with cerebral palsy."</div>
                
                
                <div class="evidence-explanation">Identifies spasticity as a dominant feature frequently confused with cerebral palsy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">5</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Seizures
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                                Seizure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001250)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Seizures in hyperargininemia may be more common than reported in previous studies."</div>
                
                
                <div class="evidence-explanation">Directly supports that seizures are frequent and potentially underreported.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic encephalopathy is not usually observed."</div>
                
                
                <div class="evidence-explanation">Confirms distinct clinical presentation where seizures, not hyperammonemic encephalopathy, dominate.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Intellectual disability
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001249" target="_blank">
                                Intellectual disability
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001249)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."</div>
                
                
                <div class="evidence-explanation">Directly identifies progressive intellectual impairment as a clinical feature of ARG1 deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Global developmental delay
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001263" target="_blank">
                                Global developmental delay
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001263)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Developmental delay is commonly reported in hyperargininemia case series, though specific frequency data from published abstracts are limited.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Encephalopathy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001298" target="_blank">
                                Encephalopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001298)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic encephalopathy is not usually observed."</div>
                
                
                <div class="evidence-explanation">Confirms that hyperammonemic encephalopathy can occur but is not a usual finding.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Abnormal cerebral white matter morphology
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002500" target="_blank">
                                Abnormal cerebral white matter morphology
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002500)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Features distinguishing hyperargininemia from cerebral palsy and hereditary spastic paraplegia are emphasized in this large series of patients."</div>
                
                
                <div class="evidence-explanation">Clinical and neuroimaging findings help distinguish hyperargininemia from other spastic disorders.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Growth retardation
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0004322" target="_blank">
                                Short stature
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0004322)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."</div>
                
                
                <div class="evidence-explanation">Identifies persistent growth retardation as a characteristic feature of ARG1 deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Spastic paraparesis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002313" target="_blank">
                                Spastic paraparesis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002313)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."</div>
                
                
                <div class="evidence-explanation">Identifies spastic paraparesis as a hallmark feature of ARG1 deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical presentation and progression were evident in our series."</div>
                
                
                <div class="evidence-explanation">Confirms progressive spastic diplegia as the key clinical abnormality in a 16-patient cohort.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyperammonemia
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001987" target="_blank">
                                Hyperammonemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001987)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."</div>
                
                
                <div class="evidence-explanation">Describes hyperammonemia as infrequent but present during catabolic stress.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38292042" target="_blank">PMID:38292042</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality."</div>
                
                
                <div class="evidence-explanation">Confirms that metabolite accumulation is part of the ARG1-D clinical spectrum.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyperargininemia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0500153" target="_blank">
                                Hyperargininemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0500153)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38292042" target="_blank">PMID:38292042</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality."</div>
                
                
                <div class="evidence-explanation">Confirms marked increases in plasma arginine as the defining biochemical characteristic.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."</div>
                
                
                <div class="evidence-explanation">Identifies hyperargininemia as the primary biochemical finding in ARG1 deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ARG1 pathogenic variants
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea."</div>
                
                
                <div class="evidence-explanation">Describes the genetic basis including mutation spectrum and functional consequences.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Protein-restricted diet
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dietary protein restriction with supplementation of essential amino acids is the cornerstone of chronic management. The primary goal is to reduce plasma arginine concentration below 200 umol/L, though this target is rarely achievable with diet alone due to endogenous arginine production.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Nitrogen scavenger therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Nitrogen scavengers including sodium benzoate, sodium phenylbutyrate, and sodium phenylacetate are used to provide alternative pathways for nitrogen excretion, particularly during hyperammonemic episodes and as chronic adjunctive therapy.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Pegzilarginase enzyme replacement therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Pegzilarginase is a pegylated recombinant human arginase 1 enzyme therapy that represents the first potential disease-modifying treatment for ARG1-D. In the Phase 3 PEACE trial, weekly pegzilarginase reduced geometric mean plasma arginine from 354 to 86 umol/L at 24 weeks, normalizing levels in 90.5% of patients compared to 0% with placebo, with clinically relevant functional mobility improvements.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38292042" target="_blank">PMID:38292042</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In addition, clinically relevant functional mobility improvements were demonstrated with pegzilarginase treatment. These effects were sustained long-term through additional 24 weeks of subsequent exposure."</div>
                
                
                <div class="evidence-explanation">Demonstrates sustained clinical mobility improvements beyond biochemical correction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Liver transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001175" target="_blank">
                            MAXO:0001175
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Liver transplantation can restore hepatic urea cycle function and halt neurological deterioration. It is considered for patients with severe metabolic instability refractory to medical management.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antispasticity management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Symptomatic treatment of spasticity with physical therapy, botulinum toxin injections, and oral antispasticity agents to maintain mobility and prevent contractures. Early intervention is important given the progressive nature of the motor involvement.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with cerebral palsy."</div>
                
                
                <div class="evidence-explanation">Identifying the treatable nature of spasticity supports active spasticity management.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antiepileptic therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Seizure management with appropriate antiepileptic drugs, given that seizures occur in 60-75% of patients. Seizure control is an important aspect of supportive care.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22633632" target="_blank">PMID:22633632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Seizures in hyperargininemia may be more common than reported in previous studies."</div>
                
                
                <div class="evidence-explanation">High seizure frequency supports the need for antiepileptic management.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Newborn screening
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000124" target="_blank">
                            MAXO:0000124
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Arginase deficiency is detectable by newborn screening using tandem mass spectrometry with elevated arginine as the primary marker. Use of the arginine-to-ornithine ratio improves sensitivity and specificity, as neonatal arginine levels may appear near-normal due to maternal arginase or ARG2 activity.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28659245" target="_blank">PMID:28659245</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Improved newborn screening effectiveness should lead to better case detection and more rapid treatment to lower plasma arginine levels hence improving long term outcome of individuals with hyperargininemia."</div>
                
                
                <div class="evidence-explanation">Supports early detection through newborn screening for improved outcomes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling for affected families including discussion of autosomal recessive inheritance, 25% recurrence risk, carrier testing, and prenatal diagnostic options. Carrier screening implications are increasingly recognized given the expanding understanding of ARG1 variant pathogenicity.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis."</div>
                
                
                <div class="evidence-explanation">Autosomal recessive inheritance pattern supports the role of genetic counseling.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Plasma arginine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Markedly elevated plasma arginine is the hallmark biochemical abnormality, with levels often exceeding 300 umol/L (normal upper limit approximately 75 umol/L). The therapeutic target is to reduce plasma arginine below 200 umol/L. Arginine is the primary biomarker for diagnosis, monitoring, and therapeutic response assessment.
</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Guanidino compounds
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Guanidino compounds including guanidinoacetate and alpha-keto-guanidinovalerate are elevated in blood, CSF, and brain tissue of ARG1-deficient patients. These neurotoxic metabolites are implicated in the progressive neurological deterioration through inhibition of GABAergic and glycinergic neurotransmission and induction of oxidative stress.
</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Ornithine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Reduced ornithine production results from impaired ARG1-mediated arginine hydrolysis. The arginine-to-ornithine ratio is a useful diagnostic discriminator in newborn screening, with a ratio of 1.4 or greater supporting identification of affected individuals.
</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Ammonia
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Episodic hyperammonemia occurs during catabolic stress but is notably less frequent than in other urea cycle disorders. Ammonia elevations are typically moderate and intermittent rather than severe and persistent.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."</div>
                
                
                <div class="evidence-explanation">Describes hyperammonemia as infrequent but present in ARG1 deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Erythrocyte arginase activity
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: ARG1 activity measured in erythrocytes is reduced or absent in affected patients. Erythrocyte arginase assay serves as a functional confirmatory test alongside genetic testing and amino acid analysis.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea."</div>
                
                
                <div class="evidence-explanation">Supports reduced or absent ARG1 enzyme activity as a diagnostic finding.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Urea
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Urea production is reduced due to impaired ARG1-mediated conversion of arginine to urea and ornithine, reflecting the fundamental block in the final step of the urea cycle.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26467175" target="_blank">PMID:26467175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle, leading to impaired ureagenesis."</div>
                
                
                <div class="evidence-explanation">Directly states impaired ureagenesis as a consequence of ARG1 deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Arginase Deficiency
category: Mendelian
creation_date: &#39;2025-06-12T20:16:27Z&#39;
updated_date: &#39;2026-02-28T02:48:34Z&#39;
synonyms:
- Argininemia
- Hyperargininemia
- ARG1 deficiency
- Arginase 1 deficiency
description: &#39;Arginase 1 (ARG1) deficiency is a rare autosomal recessive urea cycle disorder caused by biallelic pathogenic
  variants in the ARG1 gene. ARG1 catalyzes the final step of the urea cycle, hydrolyzing L-arginine to ornithine and urea.
  Loss of ARG1 activity leads to persistent hyperargininemia and accumulation of neurotoxic guanidino compounds, with relatively
  infrequent hyperammonemia compared to other urea cycle disorders. The hallmark clinical presentation includes progressive
  spastic diplegia or paraparesis, seizures, intellectual disability, and growth retardation, typically manifesting in early
  childhood. The estimated global birth prevalence is approximately 2.8 per 1,000,000 live births.

  &#39;
disease_term:
  preferred_term: arginase deficiency
  term:
    id: MONDO:0008814
    label: arginase deficiency
parents:
- Urea Cycle Disorder
- Inborn Error of Metabolism
prevalence:
- population: Global
  notes: &#39;Estimated global birth prevalence is approximately 2.8 cases per 1,000,000 live births, with a population prevalence
    of approximately 1.4 cases per 1,000,000 people.

    &#39;
  evidence:
  - reference: PMID:39669610
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Mutant allele frequency estimates ranged from 17 to 266 per 100,000 and birth prevalence from 1 in 141,331 to
      34,602,076.
    explanation: Provides birth prevalence range estimates based on allele frequency analysis.
progression:
- phase: Neonatal biochemical phase
  notes: &#39;Persistent hyperargininemia develops in infancy. Newborn screening may miss cases because plasma arginine levels
    may appear normal or near-normal due to maternal arginase or ARG2 activity. Arginine-to-ornithine ratio improves detection
    sensitivity.

    &#39;
- phase: Progressive neurological deterioration
  age_range: Early childhood through adolescence
  notes: &#39;Progressive spastic diplegia or paraparesis typically emerges in early childhood, with seizures and cognitive decline
    following. Accumulation of guanidino compounds drives neurotoxicity. Late disease features include cerebral and cerebellar
    atrophy, corticospinal tract degeneration, and progressive mobility impairment.

    &#39;
  evidence:
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical
      presentation and progression were evident in our series.
    explanation: Describes the progressive neurological course with variability.
pathophysiology:
- name: ARG1 molecular function deficiency
  description: &#39;Biallelic pathogenic ARG1 variants reduce arginase catalytic
    activity in hepatocytes.

    &#39;
  genes:
  - preferred_term: ARG1
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Supports ARG1 deficiency as the initiating molecular defect in arginase deficiency.
  downstream:
  - target: Impaired ureagenesis and hyperargininemia
    description: Loss of ARG1 catalytic function reduces terminal urea-cycle flux and elevates arginine.
- name: Impaired ureagenesis and hyperargininemia
  description: &#39;Loss of ARG1 activity causes persistent hyperargininemia with
    plasma arginine levels exceeding 300 umol/L, impaired nitrogen disposal, and
    intermittent hyperammonemia during catabolic stress. Unlike other urea cycle
    disorders, hyperammonemia is relatively infrequent, and the dominant disease
    driver is chronic arginine toxicity.

    &#39;
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  - preferred_term: arginine catabolic process
    term:
      id: GO:0006527
      label: arginine catabolic process
  evidence:
  - reference: PMID:38292042
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized
      by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions
      in quality of life, and premature mortality.
    explanation: Confirms hyperargininemia as the central biochemical feature of ARG1-D.
  downstream:
  - target: Neurotoxicity from guanidino compound accumulation
  - target: Arginine-nitric oxide pathway dysregulation
- name: Neurotoxicity from guanidino compound accumulation
  description: &#39;Accumulation of arginine and its downstream guanidino compound derivatives contributes to neurotoxicity through
    multiple mechanisms including inhibition of GABAergic and glycinergic neurotransmission, disruption of Na+/K+-ATPase activity,
    and induction of oxidative stress in brain tissue. These neurotoxic effects underlie the progressive neurological deterioration
    characteristic of the disease.

    &#39;
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:26467175
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: This review briefly highlights the current understanding of the etiology and pathophysiology of ARG1 deficiency
      derived from clinical case reports and therapeutic strategies stretching over several decades and reports on several
      exciting new developments regarding the pathophysiology of the disorder using ARG1 global and inducible knockout mouse
      models.
    explanation: Reviews pathophysiology of ARG1 deficiency but the abstract does not specifically detail guanidino compound
      neurotoxic mechanisms.
  downstream:
  - target: White matter pathology and dysmyelination
- name: White matter pathology and dysmyelination
  description: &#39;Central nervous system white matter pathology with dysmyelination and corticospinal tract degeneration is
    a key substrate for progressive spasticity in ARG1 deficiency. Preclinical studies demonstrate that hepatic ARG1 restoration
    via mRNA therapy can improve CNS myelination in arginase-deficient mice, suggesting that systemic arginine reduction has
    downstream CNS benefits.

    &#39;
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  evidence:
  - reference: PMID:39449289
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult
      citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency, in the
      latter case has progressed to the clinical trials phase.
    explanation: Confirms preclinical mRNA therapy testing for arginase deficiency but does not specifically address myelination
      outcomes.
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical
      presentation and progression were evident in our series.
    explanation: Clinical evidence of progressive spasticity consistent with corticospinal tract and white matter pathology.
- name: Arginine-nitric oxide pathway dysregulation
  description: &#39;Arginine is a shared substrate for arginase and nitric oxide synthase (NOS). Loss of ARG1 activity shifts
    arginine partitioning and may perturb nitric oxide and polyamine biosynthesis, with implications for vascular function
    and cellular signaling. ARG1 is also expressed in erythrocytes and immune cells, suggesting broader metabolic consequences
    beyond the hepatic urea cycle.

    &#39;
  biological_processes:
  - preferred_term: nitric oxide biosynthetic process
    term:
      id: GO:0006809
      label: nitric oxide biosynthetic process
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  evidence:
  - reference: PMID:26467175
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Finally, some of the functions and implications of ARG1 in non-urea cycle activities are considered.
    explanation: Mentions non-urea cycle ARG1 activities but does not specifically detail NO pathway dysregulation in the abstract.
phenotypes:
- name: Spastic paraparesis
  frequency: VERY_FREQUENT
  description: &#39;Progressive spastic diplegia or paraparesis is the hallmark neurological feature, typically presenting in
    early childhood. Upper motor neuron involvement occurs in approximately 80% of patients, often initially mistaken for
    cerebral palsy.

    &#39;
  phenotype_term:
    preferred_term: Spastic paraparesis
    term:
      id: HP:0002313
      label: Spastic paraparesis
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual
      impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs
      strikingly from other urea cycle disorders.
    explanation: Identifies spastic paraparesis as a hallmark feature of ARG1 deficiency.
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Progressive spastic diplegia constituted the key clinical abnormality in this group, but variability in clinical
      presentation and progression were evident in our series.
    explanation: Confirms progressive spastic diplegia as the key clinical abnormality in a 16-patient cohort.
- name: Hyperammonemia
  frequency: OCCASIONAL
  description: &#39;Episodic hyperammonemia occurs during catabolic stress, but is notably less frequent than in other urea cycle
    disorders. This distinguishing feature reflects the unique position of ARG1 as the terminal urea cycle enzyme with partial
    compensatory activity from ARG2.

    &#39;
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual
      impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs
      strikingly from other urea cycle disorders.
    explanation: Describes hyperammonemia as infrequent but present during catabolic stress.
  - reference: PMID:38292042
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized
      by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions
      in quality of life, and premature mortality.
    explanation: Confirms that metabolite accumulation is part of the ARG1-D clinical spectrum.
- name: Seizures
  frequency: FREQUENT
  description: &#39;Seizures occur in approximately 60-75% of patients and are linked to the epileptogenic properties of accumulated
    guanidino compounds. Seizure frequency may be more common than historically reported.

    &#39;
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures in hyperargininemia may be more common than reported in previous studies.
    explanation: Directly supports that seizures are frequent and potentially underreported.
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It
      is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic
      encephalopathy is not usually observed.
    explanation: Confirms distinct clinical presentation where seizures, not hyperammonemic encephalopathy, dominate.
- name: Intellectual disability
  frequency: FREQUENT
  description: &#39;Progressive intellectual impairment is a common feature, often developing in early childhood alongside motor
    deterioration. The cognitive decline is attributed to chronic neurotoxicity from accumulated arginine and guanidino compounds.

    &#39;
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual
      impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs
      strikingly from other urea cycle disorders.
    explanation: Directly identifies progressive intellectual impairment as a clinical feature of ARG1 deficiency.
- name: Global developmental delay
  frequency: FREQUENT
  description: &#39;Developmental delay is common, often preceding the recognition of spastic paraparesis and intellectual disability.
    Motor milestones may be delayed or lost as the disease progresses.

    &#39;
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  notes: Developmental delay is commonly reported in hyperargininemia case series, though specific frequency data from
    published abstracts are limited.
- name: Growth retardation
  frequency: VERY_FREQUENT
  description: &#39;Persistent growth retardation is a characteristic feature, likely reflecting chronic catabolic stress and
    dietary protein restriction. Short stature is observed in the majority of patients.

    &#39;
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual
      impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs
      strikingly from other urea cycle disorders.
    explanation: Identifies persistent growth retardation as a characteristic feature of ARG1 deficiency.
- name: Spasticity
  frequency: VERY_FREQUENT
  description: &#39;Upper and lower extremity spasticity is a predominant motor finding, with corticospinal tract involvement.
    This is the feature most often leading to initial clinical evaluation and may be mistaken for cerebral palsy.

    &#39;
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with
      cerebral palsy.
    explanation: Identifies spasticity as a dominant feature frequently confused with cerebral palsy.
- name: Encephalopathy
  frequency: OCCASIONAL
  description: &#39;Acute or recurrent encephalopathy may occur during hyperammonemic crises triggered by catabolic stress, though
    this is less common than in other urea cycle disorders.

    &#39;
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I. It
      is a rare pan-ethnic disease with a clinical presentation distinct from that of other urea cycle disorders, and hyperammonemic
      encephalopathy is not usually observed.
    explanation: Confirms that hyperammonemic encephalopathy can occur but is not a usual finding.
- name: Hepatomegaly
  frequency: OCCASIONAL
  description: &#39;Hepatic involvement including hepatomegaly may occur, reflecting the primary hepatic expression of ARG1 and
    metabolic stress on the liver.

    &#39;
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  notes: Hepatomegaly has been reported in case reports of ARG1 deficiency but robust frequency data are lacking.
- name: Hyperargininemia
  frequency: VERY_FREQUENT
  description: &#39;Persistent elevation of plasma arginine, often exceeding 300 umol/L, is the defining biochemical feature.
    Plasma arginine levels are the primary biomarker for disease monitoring and therapeutic response.

    &#39;
  phenotype_term:
    preferred_term: Hyperargininemia
    term:
      id: HP:0500153
      label: Hyperargininemia
  evidence:
  - reference: PMID:38292042
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized
      by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions
      in quality of life, and premature mortality.
    explanation: Confirms marked increases in plasma arginine as the defining biochemical characteristic.
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual
      impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs
      strikingly from other urea cycle disorders.
    explanation: Identifies hyperargininemia as the primary biochemical finding in ARG1 deficiency.
- name: Abnormal cerebral white matter morphology
  frequency: FREQUENT
  description: &#39;Neuroimaging abnormalities including white matter changes, cerebral atrophy, and cerebellar atrophy are commonly
    observed and correlate with the progressive neurological deterioration.

    &#39;
  phenotype_term:
    preferred_term: Abnormal cerebral white matter morphology
    term:
      id: HP:0002500
      label: Abnormal cerebral white matter morphology
  evidence:
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Features distinguishing hyperargininemia from cerebral palsy and hereditary spastic paraplegia are emphasized
      in this large series of patients.
    explanation: Clinical and neuroimaging findings help distinguish hyperargininemia from other spastic disorders.
- name: Microcephaly
  frequency: OCCASIONAL
  description: &#39;Microcephaly has been reported in some patients, likely reflecting the chronic neurotoxic effects on brain
    development during critical periods of growth.

    &#39;
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  notes: Microcephaly has been reported in some ARG1-deficient patients but the abstract does not specifically quantify
    this finding.
biochemical:
- name: Plasma arginine
  presence: INCREASED
  context: &#39;Markedly elevated plasma arginine is the hallmark biochemical abnormality, with levels often exceeding 300 umol/L
    (normal upper limit approximately 75 umol/L). The therapeutic target is to reduce plasma arginine below 200 umol/L. Arginine
    is the primary biomarker for diagnosis, monitoring, and therapeutic response assessment.

    &#39;
- name: Guanidino compounds
  presence: INCREASED
  context: &#39;Guanidino compounds including guanidinoacetate and alpha-keto-guanidinovalerate are elevated in blood, CSF, and
    brain tissue of ARG1-deficient patients. These neurotoxic metabolites are implicated in the progressive neurological deterioration
    through inhibition of GABAergic and glycinergic neurotransmission and induction of oxidative stress.

    &#39;
- name: Ornithine
  presence: DECREASED
  context: &#39;Reduced ornithine production results from impaired ARG1-mediated arginine hydrolysis. The arginine-to-ornithine
    ratio is a useful diagnostic discriminator in newborn screening, with a ratio of 1.4 or greater supporting identification
    of affected individuals.

    &#39;
- name: Ammonia
  presence: INCREASED
  context: &#39;Episodic hyperammonemia occurs during catabolic stress but is notably less frequent than in other urea cycle disorders.
    Ammonia elevations are typically moderate and intermittent rather than severe and persistent.

    &#39;
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual
      impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs
      strikingly from other urea cycle disorders.
    explanation: Describes hyperammonemia as infrequent but present in ARG1 deficiency.
- name: Erythrocyte arginase activity
  presence: DECREASED
  context: &#39;ARG1 activity measured in erythrocytes is reduced or absent in affected patients. Erythrocyte arginase assay serves
    as a functional confirmatory test alongside genetic testing and amino acid analysis.

    &#39;
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting
      in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
    explanation: Supports reduced or absent ARG1 enzyme activity as a diagnostic finding.
- name: Urea
  presence: DECREASED
  context: &#39;Urea production is reduced due to impaired ARG1-mediated conversion of arginine to urea and ornithine, reflecting
    the fundamental block in the final step of the urea cycle.

    &#39;
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle,
      leading to impaired ureagenesis.
    explanation: Directly states impaired ureagenesis as a consequence of ARG1 deficiency.
genetic:
- name: ARG1 pathogenic variants
  inheritance:
  - name: Autosomal recessive
    description: &#39;Arginase 1 deficiency follows autosomal recessive inheritance. Both parents are obligate carriers with a
      25% recurrence risk for each pregnancy.

      &#39;
    evidence:
    - reference: PMID:26467175
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle,
        leading to impaired ureagenesis.
      explanation: Directly identifies autosomal recessive inheritance.
    - reference: PMID:22633632
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hyperargininemia is an autosomal recessive metabolic disorder caused by a deficiency of enzyme arginase I.
      explanation: Confirms autosomal recessive inheritance in an independent clinical cohort.
  variants:
  - name: Various ARG1 pathogenic variants
    description: &#39;More than 40 pathogenic mutations have been identified across the ARG1 gene on chromosome 6q23, distributed
      fairly uniformly throughout the gene. Variants include missense, nonsense, frameshift, and splice-site mutations resulting
      in partial or complete loss of enzyme function.

      &#39;
  features: &#39;Biallelic pathogenic variants in ARG1 cause loss of arginase 1 enzyme activity. The gene is located on chromosome
    6q23 and encodes a trimeric manganese-dependent metalloprotein. Genotype-phenotype correlations are incomplete, but complete
    loss of function generally leads to more severe disease. Residual enzyme activity may account for clinical variability.
    More than 73 published ARG1 variants have been identified, of which 46 are classified as pathogenic or likely pathogenic.

    &#39;
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This genetic disorder is caused by 40+ mutations found fairly uniformly spread throughout the ARG1 gene, resulting
      in partial or complete loss of enzyme function, which catalyzes the hydrolysis of arginine to ornithine and urea.
    explanation: Describes the genetic basis including mutation spectrum and functional consequences.
treatments:
- name: Protein-restricted diet
  description: &#39;Dietary protein restriction with supplementation of essential amino acids is the cornerstone of chronic management.
    The primary goal is to reduce plasma arginine concentration below 200 umol/L, though this target is rarely achievable
    with diet alone due to endogenous arginine production.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  notes: Dietary protein restriction is a well-established cornerstone of ARG1 deficiency management, but direct evidence
    for its efficacy from controlled trials is lacking. The pegzilarginase trial was motivated in part by the insufficiency
    of diet alone to normalize plasma arginine.
- name: Nitrogen scavenger therapy
  description: &#39;Nitrogen scavengers including sodium benzoate, sodium phenylbutyrate, and sodium phenylacetate are used to
    provide alternative pathways for nitrogen excretion, particularly during hyperammonemic episodes and as chronic adjunctive
    therapy.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  notes: Nitrogen scavengers are a standard part of UCD management, used adjunctively with dietary protein restriction.
    Direct trial evidence specific to ARG1 deficiency is limited compared to other UCDs.
- name: Pegzilarginase enzyme replacement therapy
  description: &#39;Pegzilarginase is a pegylated recombinant human arginase 1 enzyme therapy that represents the first potential
    disease-modifying treatment for ARG1-D. In the Phase 3 PEACE trial, weekly pegzilarginase reduced geometric mean plasma
    arginine from 354 to 86 umol/L at 24 weeks, normalizing levels in 90.5% of patients compared to 0% with placebo, with
    clinically relevant functional mobility improvements.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38292042
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, clinically relevant functional mobility improvements were demonstrated with pegzilarginase treatment.
      These effects were sustained long-term through additional 24 weeks of subsequent exposure.
    explanation: Demonstrates sustained clinical mobility improvements beyond biochemical correction.
- name: Liver transplantation
  description: &#39;Liver transplantation can restore hepatic urea cycle function and halt neurological deterioration. It is considered
    for patients with severe metabolic instability refractory to medical management.

    &#39;
  treatment_term:
    preferred_term: liver transplantation
    term:
      id: MAXO:0001175
      label: liver transplantation
- name: Antispasticity management
  description: &#39;Symptomatic treatment of spasticity with physical therapy, botulinum toxin injections, and oral antispasticity
    agents to maintain mobility and prevent contractures. Early intervention is important given the progressive nature of
    the motor involvement.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperargininemia is one of the few treatable causes of pediatric spastic paraparesis, and can be confused with
      cerebral palsy.
    explanation: Identifying the treatable nature of spasticity supports active spasticity management.
- name: Antiepileptic therapy
  description: &#39;Seizure management with appropriate antiepileptic drugs, given that seizures occur in 60-75% of patients.
    Seizure control is an important aspect of supportive care.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:22633632
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures in hyperargininemia may be more common than reported in previous studies.
    explanation: High seizure frequency supports the need for antiepileptic management.
- name: Newborn screening
  description: &#39;Arginase deficiency is detectable by newborn screening using tandem mass spectrometry with elevated arginine
    as the primary marker. Use of the arginine-to-ornithine ratio improves sensitivity and specificity, as neonatal arginine
    levels may appear near-normal due to maternal arginase or ARG2 activity.

    &#39;
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:28659245
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Improved newborn screening effectiveness should lead to better case detection and more rapid treatment to lower
      plasma arginine levels hence improving long term outcome of individuals with hyperargininemia.
    explanation: Supports early detection through newborn screening for improved outcomes.
- name: Genetic counseling
  description: &#39;Genetic counseling for affected families including discussion of autosomal recessive inheritance, 25% recurrence
    risk, carrier testing, and prenatal diagnostic options. Carrier screening implications are increasingly recognized given
    the expanding understanding of ARG1 variant pathogenicity.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:26467175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Arginase-1 (ARG1) deficiency is a rare autosomal recessive disorder that affects the liver-based urea cycle,
      leading to impaired ureagenesis.
    explanation: Autosomal recessive inheritance pattern supports the role of genetic counseling.
notes: &#39;Key distinguishing features of ARG1 deficiency among urea cycle disorders: (1) hyperammonemia is infrequent rather
  than dominant; (2) progressive spastic paraparesis is the hallmark presentation; (3) the disease is often initially confused
  with cerebral palsy or hereditary spastic paraplegia; (4) chronic arginine toxicity and guanidino compound accumulation
  drive neurological injury rather than acute ammonia crises. The Phase 3 PEACE trial of pegzilarginase represents a major
  advance, demonstrating that sustained arginine normalization is achievable and associated with functional mobility improvements.
  Gene therapy and mRNA therapeutic approaches are in preclinical development. Caution is warranted in extrapolating mouse
  model findings, as the lethal disease phenotype in mice is substantially more severe than in humans.

  &#39;
references: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Arginase_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>